AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21311502 — intervention group
Group type: COMPARATOR
Intervention: Immediate Kangaroo Mother Care (KMC), where newborns are held skin-to-skin (STS) on mother's chest for less than 7 hours per day in the first 2 days of life.
Number of subjects: 0
Study 21311502 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based KMC (CKMC) implementation
Number of subjects: 0
Study 19477398 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol IR twice daily (BID)
Number of subjects: 405
Study 19477398 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol CR once daily (QD)
Number of subjects: 405
Study 19477398 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol CR taken in the morning and placebo in the afternoon
Number of subjects: 405
Study 19477398 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol IR
Number of subjects: 405
Study 18257352 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Channel (acupuncture at five-shu-points)
Number of subjects: 60
Study 18257352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Channel (acupuncture at five-shu-points)
Number of subjects: 60
Study 15650498 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 40
Study 15650498 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 40
Study 11142332 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice career pathway development
Number of subjects: 1000
Study 11142332 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice education delivery
Number of subjects: 1000
Study 9276050 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 60
Study 9276050 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 60
Study 8319653 — intervention group
Group type: COMPARATOR
Intervention: Monochloramine 2 ppm
Number of subjects: 48
Study 8319653 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochloramine 15 ppm
Number of subjects: 48
Study 8319653 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 48
Study 3789388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.2 microgram/kg bw per minute)
Number of subjects: 70
Study 3789388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.1 microgram/kg bw per minute)
Number of subjects: 70
Study 3789388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3789388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.2 microgram/kg bw per minute) during ECC
Number of subjects: 70
Study 3789388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.1 microgram/kg bw per minute) during ECC
Number of subjects: 70
Study 3789388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 70
Study 30932889 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Supplement Containing Astaxanthin and Sesamin
Number of subjects: 0
Study 30932889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30165840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 80
Study 30165840 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 80
Study 30165840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser combined with NaOCl
Number of subjects: 80
Study 30165840 — intervention group
Group type: COMPARATOR
Intervention: Negative group (no treatment)
Number of subjects: 80
Study 27687471 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipped hair using disposable electric clippers
Number of subjects: 1678
Study 27687471 — intervention group
Group type: COMPARATOR
Intervention: Not clipped (no hair removal)
Number of subjects: 1678
Study 25891549 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 359
Study 25891549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 23451461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg triamcinolone
Number of subjects: 104
Study 23451461 — intervention group
Group type: COMPARATOR
Intervention: 10 mg triamcinolone
Number of subjects: 104
Study 20450940 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate responses to standardized trauma-related pictures
Number of subjects: 162
Study 20450940 — intervention group
Group type: COMPARATOR
Intervention: Heart rate responses to generally threatening pictures
Number of subjects: 162
Study 20450940 — intervention group
Group type: COMPARATOR
Intervention: Heart rate responses to neutral pictures
Number of subjects: 162
Study 20450940 — intervention group
Group type: EXPERIMENTAL
Intervention: HR responses to trauma-related pictures
Number of subjects: 162
Study 18687720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones (50 hour programme)
Number of subjects: 2776
Study 18687720 — intervention group
Group type: COMPARATOR
Intervention: Three hour intervention on HIV and safer sex (Control)
Number of subjects: 2776
Study 16411499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic natural images at high contrasts
Number of subjects: 0
Study 16411499 — intervention group
Group type: COMPARATOR
Intervention: Narrow band stimuli at low contrasts
Number of subjects: 0
Study 12878022 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 428
Study 12878022 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 428
Study 12878022 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowns
Number of subjects: 428
Study 12878022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 428
Study 10829585 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-antagonists (non dihydropyridinic compounds)
Number of subjects: 0
Study 10829585 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment or placebo)
Number of subjects: 0
Study 8975835 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative catheterization in inferior Q-wave infarction group (11 patients)
Number of subjects: 194
Study 8975835 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative catheterization in anterior Q-wave infarction group (6 patients)
Number of subjects: 194
Study 8975835 — intervention group
Group type: EXPERIMENTAL
Intervention: Average peak postoperative creatine kinase MB levels
Number of subjects: 194
Study 8975835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 3 years in patients with Q-wave infarctions
Number of subjects: 194
Study 1414968 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene/d
Number of subjects: 0
Study 1414968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4003667 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate treatment (MIT, n = 202)
Number of subjects: 250
Study 4003667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MIP, n = 198)
Number of subjects: 250
Study 30636728 — intervention group
Group type: COMPARATOR
Intervention: Stabilizing exercises (Group A)
Number of subjects: 40
Study 30636728 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing exercises + pelvic floor muscles training (Group B)
Number of subjects: 40
Study 28204953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aln-NEF alone (70 mg)
Number of subjects: 30
Study 28204953 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4 alone (600 μg)
Number of subjects: 30
Study 28204953 — intervention group
Group type: COMPARATOR
Intervention: Aln-NEF and LT4 concurrently
Number of subjects: 30
Study 26050015 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan (GM)
Number of subjects: 199
Study 26050015 — intervention group
Group type: EXPERIMENTAL
Intervention: β-D-glucan (BG)
Number of subjects: 199
Study 23188041 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana-related visual cues
Number of subjects: 12
Study 22097204 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 60
Study 19497149 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg pre-pregnancy body weight)
Number of subjects: 27
Study 19497149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gelatin capsule)
Number of subjects: 27
Study 16988210 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin administered as an oral lyophilisate dosage form; specific dosage and duration not mentioned.
Number of subjects: 0
Study 16988210 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin in children with nocturnal enuresis; specific dosage and duration not mentioned.
Number of subjects: 0
Study 16988210 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin in healthy adults; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15531011 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart injected immediately before the meal
Number of subjects: 20
Study 15531011 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart injected immediately after the meal
Number of subjects: 20
Study 11309011 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% ropivacaine with 50 IU/ml hyaluronidase
Number of subjects: 40
Study 11309011 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine with 50 IU/ml hyaluronidase
Number of subjects: 40
Study 9322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (17.8 mumol Cr/d or 924 micrograms Cr/d)
Number of subjects: 18
Study 9322572 — intervention group
Group type: COMPARATOR
Intervention: Low-chromium placebo
Number of subjects: 18
Study 9322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training
Number of subjects: 18
Study 9322572 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation + Resistive training
Number of subjects: 18
Study 7936311 — intervention group
Group type: EXPERIMENTAL
Intervention: deprenyl (10 mg/d)
Number of subjects: 800
Study 7936311 — intervention group
Group type: EXPERIMENTAL
Intervention: tocopherol (2,000 IU/d)
Number of subjects: 800
Study 7936311 — intervention group
Group type: EXPERIMENTAL
Intervention: both deprenyl and tocopherol
Number of subjects: 800
Study 7936311 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 800
Study 3070134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol (0.5%)
Number of subjects: 26
Study 3070134 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5%)
Number of subjects: 26
Study 2405749 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 52
Study 5472805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise inhalation of disodium cromoglycate
Number of subjects: 52
Study 30873800 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of hepatitis B
Number of subjects: 358
Study 30873800 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of transmission methods
Number of subjects: 358
Study 30873800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean knowledge score
Number of subjects: 358
Study 30873800 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle recapping behavior
Number of subjects: 358
Study 30873800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 358
Study 28621003 — intervention group
Group type: EXPERIMENTAL
Intervention: BPT+AM
Number of subjects: 110
Study 28621003 — intervention group
Group type: COMPARATOR
Intervention: BPT
Number of subjects: 110
Study 26180226 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling focused on cessation goals and beliefs
Number of subjects: 522
Study 26180226 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 522
Study 26180226 — intervention group
Group type: COMPARATOR
Intervention: Low contact control group
Number of subjects: 522
Study 26180226 — intervention group
Group type: COMPARATOR
Intervention: Motivated to quit (comparison group)
Number of subjects: 522
Study 23432889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 0
Study 23432889 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 21292872 — intervention group
Group type: EXPERIMENTAL
Intervention: Duffy (+) subjects exposed to P. vivax-infected mosquitoes
Number of subjects: 22
Study 21292872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Duffy +)
Number of subjects: 22
Study 21292872 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups B and C (Duffy +)
Number of subjects: 22
Study 21292872 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment post-infection
Number of subjects: 22
Study 21292872 — intervention group
Group type: COMPARATOR
Intervention: Duffy (‐) subjects
Number of subjects: 22
Study 19906517 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphomonoester narrow resonance
Number of subjects: 54
Study 16303216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg PRP-T
Number of subjects: 1048
Study 16303216 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 microg PRP-T
Number of subjects: 1048
Study 16303216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg PRP-T
Number of subjects: 1048
Study 16303216 — intervention group
Group type: EXPERIMENTAL
Intervention: 4th booster dose of Hib
Number of subjects: 1048
Study 16303216 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary immunization
Number of subjects: 1048
Study 16303216 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccination alone
Number of subjects: 1048
Study 12531776 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly isoniazid/rifapentine
Number of subjects: 133
Study 12531776 — intervention group
Group type: COMPARATOR
Intervention: Control cases (not specified but implied to be twice-weekly isoniazid/rifampin)
Number of subjects: 133
Study 12531776 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly isoniazid/rifampin
Number of subjects: 133
Study 12170675 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeediCath (Coloplast)
Number of subjects: 27
Study 12170675 — intervention group
Group type: COMPARATOR
Intervention: Lofric (Astra Tech)
Number of subjects: 27
Study 9663957 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistage shuttle run test
Number of subjects: 20
Study 9663957 — intervention group
Group type: COMPARATOR
Intervention: Maximal treadmill protocol
Number of subjects: 20
Study 7824961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine 7500 IU
Number of subjects: 6
Study 7824961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparine 10000 IU
Number of subjects: 6
Study 7824961 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparine 20 mg
Number of subjects: 6
Study 7824961 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparine 40 mg
Number of subjects: 6
Study 3344486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with plain bupivacaine for 48 hours and epidural morphine 4 mg every 8 hours for 96 hours plus systemic indomethacin 100 mg every 8 hours for 96 hours
Number of subjects: 24
Study 3344486 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative pain treatment with intermittent nicomorphine (10 to 15 mg) and acetaminophen (1 gm) on request
Number of subjects: 24
Study 29038876 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC filters placed <1 cm below the renal vein
Number of subjects: 333
Study 29038876 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC filters placed 1-2 cm below the renal vein
Number of subjects: 333
Study 29038876 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC filters placed >2 cm below the renal vein
Number of subjects: 333
Study 29038876 — intervention group
Group type: EXPERIMENTAL
Intervention: All filter placements
Number of subjects: 333
Study 27287781 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin at 10, 20, or 40 mg/day for 3 months
Number of subjects: 60
Study 27287781 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study 26580869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) 595 nm applied on 3 occasions (after suture removal, 15 and 45 days)
Number of subjects: 30
Study 26580869 — intervention group
Group type: COMPARATOR
Intervention: Simulated laser application
Number of subjects: 30
Study 26580869 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated half of the scar)
Number of subjects: 30
Study 23701177 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 0.7 mg daily for 40 weeks
Number of subjects: 36
Study 23701177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20876393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (0-1 M)
Number of subjects: 15
Study 20876393 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl (0-1 M)
Number of subjects: 15
Study 18599555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 44113
Study 18599555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HRT (progesterone + oestrogen)
Number of subjects: 44113
Study 16390296 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 20
Study 16390296 — intervention group
Group type: COMPARATOR
Intervention: Contact control (reading fluency training)
Number of subjects: 20
Study 12749493 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 12749493 — intervention group
Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 0
Study 11209585 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% milk
Number of subjects: 51
Study 11209585 — intervention group
Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 51
Study 9388377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)D3 (1 microgram/day) and calcium lactate
Number of subjects: 33
Study 9388377 — intervention group
Group type: COMPARATOR
Intervention: calcium lactate alone
Number of subjects: 33
Study 9388377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)D3 and calcium lactate
Number of subjects: 33
Study 7945495 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (800 micrograms/day)
Number of subjects: 50
Study 7945495 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 3074463 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg orally b.i.d. for seven days
Number of subjects: 94
Study 3074463 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) orally b.i.d. for seven days
Number of subjects: 94
Study 31012741 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-and-coping-planning intervention for forming a 'higher-order habit' of filling half of their dinner plates with fruits and vegetables
Number of subjects: 82
Study 31012741 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 82
Study 28693601 — intervention group
Group type: EXPERIMENTAL
Intervention: Model plate diet
Number of subjects: 120
Study 28693601 — intervention group
Group type: COMPARATOR
Intervention: Routine dietary advice
Number of subjects: 120
Study 26467429 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture at KI3
Number of subjects: 30
Study 26467429 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 26467429 — intervention group
Group type: COMPARATOR
Intervention: Real acupuncture at non‐acupoint
Number of subjects: 30
Study 23333902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 119
Study 23333902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 119
Study 23333902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg vs 80 mg
Number of subjects: 119
Study 21540876 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% blackcurrant juice drink (250 ml)
Number of subjects: 20
Study 21540876 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 20
Study 19417960 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% levobupivacaine
Number of subjects: 40
Study 19417960 — intervention group
Group type: COMPARATOR
Intervention: 20 ml 0.5% bupivacaine
Number of subjects: 40
Study 17558046 — intervention group
Group type: EXPERIMENTAL
Intervention: Niosomal methotrexate gel
Number of subjects: 10
Study 17558046 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10
Study 17558046 — intervention group
Group type: COMPARATOR
Intervention: Marketed methotrexate gel
Number of subjects: 10
Study 15128961 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement interventions
Number of subjects: 0
Study 15128961 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11851027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m2 (n = 28)
Number of subjects: 49
Study 11851027 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone 1 g (n = 21)
Number of subjects: 49
Study 9657119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 3 MU rIFN-alpha
Number of subjects: 63
Study 9657119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 6 MU rIFN-alpha
Number of subjects: 63
Study 9657119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 6 MU rIFN-alpha plus 14 mg/kg ribavirin
Number of subjects: 63
Study 9657119 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha plus ribavirin
Number of subjects: 63
Study 9657119 — intervention group
Group type: COMPARATOR
Intervention: rIFN-alpha
Number of subjects: 63
Study 7859893 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-active approach with patients
Number of subjects: 70
Study 7859893 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and somatic aspects of the disease
Number of subjects: 70
Study 7859893 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for co-active approach
Number of subjects: 70
Study 2737781 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 10
Study 2737781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 2737781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 10
Study 788990 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomethadone
Number of subjects: 66